RT Conference Proceedings
T1 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
A1 Cho, B. C.
A1 Rodriguez-Abreu, D.
A1 Hussein, M.
A1 Cobo, M.
A1 Patel, A.
A1 Secen, N.
A1 Gerstner, G.
A1 Kim, D-W.
A1 Lee, Y-G.
A1 Su, W-C.
A1 Huang, E.
A1 Patil, N.
A1 Huang, M.
A1 Zhang, Z.
A1 Wen, X.
A1 Mendus, D.
A1 Hoang, T.
A1 Meng, R.
A1 Johnson, M. L.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-12-10
LK https://hdl.handle.net/10668/24517
UL https://hdl.handle.net/10668/24517
LA en
DS RISalud
RD Apr 11, 2025